Moderna and Samsung Biologics announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine. Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics' facilities in Incheon, South Korea, utilizing a production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna's COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
151.5 USD | +4.21% | +2.29% | +52.15% |
02:47pm | COVID shots for JN.1 variant neutralize newer strains, vaccine makers say | RE |
06-04 | Transcript : Moderna, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.15% | 55.7B | |
+41.08% | 39.91B | |
-5.91% | 39.57B | |
-5.56% | 28.16B | |
+16.16% | 26.3B | |
-19.81% | 18.94B | |
+32.03% | 12.17B | |
+26.55% | 12.12B | |
+1.46% | 12.12B | |
-10.26% | 10.83B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine